课题基金 / 基金详情

Further Characterization of the Dolutegravir Resistance Mutation R263K: Combinations with Primary INSTI Resistance Mutations and Possible Compensatory Mechanisms

Further Characterization of the Dolutegravir Resistance Mutation R263K: Combinations with Primary INSTI Resistance Mutations and Possible Compensatory Mechanisms
多替拉韦耐药突变 R263K 的进一步表征:与主要 INSTI 耐药突变和可能的补偿机制的组合
批准号:
311953
负责人:
Anstett Kaitlin
金额:
$1.27万
依托单位:
依托单位国家:
加拿大
项目类别:
Studentship Programs
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-12-01 至 2014-12-01

项目摘要

项目成果

Anstett Kaitlin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
It is estimated that over 34 million people are currently infected with human immunodeficiency virus (HIV) worldwide. Although antiretroviral therapy has been lifesaving for many HIV-positive individuals, drug resistance threatens its long-term efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of the sequential development of integrase strand transfer inhibitor resistance mutations in HIV.
  • 批准号:
    324345
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2015
  • 负责人:
    Anstett Kaitlin
  • 依托单位:
The Modulation of R263K-Mediated HIV-1 Resistance to Integrase Strand Transfer Inhibitors by Acetylation.
  • 批准号:
    347939
  • 项目类别:
    Studentship Programs
  • 资助金额:
    $7.65万
  • 财政年份:
    2015
  • 负责人:
    Anstett Kaitlin
  • 依托单位:
Characterization of Dolutegravir Resistance Mutation R263K by Combination with Primary INSTI Resistance Mutations
  • 批准号:
    311375
  • 项目类别:
  • 资助金额:
    $0.11万
  • 财政年份:
    2014
  • 负责人:
    Anstett Kaitlin
  • 依托单位:
海外基金